Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lisata Therapeutics, Inc. (LSTA : NSDQ)

• Company Description    Lisata Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The company's principal product candidate includes LSTA1. Lisata Therapeutics Inc., formerly known as Caladrius Biosciences Inc., is based in BASKING RIDGE, N.J. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $2.74 Daily Weekly Monthly 20 Day Moving Average: 22,582 shares Shares Outstanding: 8.62 (millions) Market Capitalization: $23.61 (millions) Beta: 1.03 52 Week High: $4.20 52 Week Low: $1.87 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.08% 3.07% 12 Week 21.48% 2.18% Year To Date -8.05% -13.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 110 ALLEN ROAD SECOND FLOOR - BASKING RIDGE,NJ 07920 USA ph: 908-842-0100 fax: 646-514-7787 jmenditto@lisata.com http://www.lisata.com

• General Corporate Information    Officers David J. Mazzo - Chief Executive Officer;President and Director Gregory B. Brown - Chairman James Nisco - Senior Vice President; Finance and Treasury and Ch Steven M. Klosk - Director Cynthia L. Flowers - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 128058302 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 8.62 Most Recent Split Date: 9.00 (0.07:1) Beta: 1.03 Market Capitalization: $23.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.94 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 15.38% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -61.37 12/31/24 - -55.71 ROA 06/30/25 - - 03/31/25 - -53.35 12/31/24 - -48.74 Current Ratio 06/30/25 - - 03/31/25 - 7.52 12/31/24 - 6.16 Quick Ratio 06/30/25 - - 03/31/25 - 7.52 12/31/24 - 6.16 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -2,027.00 12/31/24 - -2,078.30 Book Value 06/30/25 - - 03/31/25 - 2.91 12/31/24 - 3.49 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©